NCT01676402View on ClinicalTrials.gov

Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years

PHASE1CompletedINTERVENTIONAL
Enrollment

316

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Influenza
Interventions
BIOLOGICAL

Seasonal Influenza DNA vaccine

VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 4 mg dosage is administered as a 1 mL volume.

BIOLOGICAL

TIV

2012/13, 2013/14 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)

Trial Locations (4)

52242

University of Iowa Hospitals & Clinics, Iowa City

63104

Saint Louis University - Doisy Research Center, St Louis

77030

Baylor College of Medicine, Houston

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
collaborator

The Emmes Company, LLC

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01676402 - Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years | Biotech Hunter | Biotech Hunter